The 3-year EFS were 66.50% (95% CI = 54.83% to 80.66%) in the HR-low/HER2-negative BC group and 75.03% (95% CI = 69.15% to 81.41%) in the TNBC group. This evidence concerns the gene ERBB2 and breast cancer.